Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -362K | 0 | -341K | 0 | 0 |
| Operating Income | -65M | -49M | -44M | -67M | -47M |
| EBITDA | -64M | -49M | -43M | -65M | -45M |
| Net Income | -57M | -45M | -40M | -66M | -47M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.98
-2.21% today
1Y Change
+41.32%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Protara Therapeutics, Inc. (TARA) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $3.98 and up 41.3% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +38.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +38.2%, free cash flow -57.4% with operating margin 0.0% and ROIC -32.3%. Stock Foundry combines TARA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TARA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TARA Max Drawdown
-51.72%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TARA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$47.3M
+28.4% YoY
Free Cash Flow
-$35.1M
-32.1% YoY
Revenue Growth
+0.0%
EPS Growth
+38.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -362K | 0 | -341K | 0 | 0 |
| Operating Income | -65M | -49M | -44M | -67M | -47M |
| EBITDA | -64M | -49M | -43M | -65M | -45M |
| Net Income | -57M | -45M | -40M | -66M | -47M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 50M | 163M | 40M | 24M | 36M |
| Total Assets | 209M | 181M | 79M | 113M | 173M |
| Total Liabilities | 13M | 14M | 11M | 11M | 11M |
| Shareholder Equity | 196M | 167M | 68M | 102M | 162M |
| Total Debt | 3M | 4M | 5M | 6M | 7M |
| Net Debt | -46M | -158M | -34M | -18M | -28M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
35M
-30.4% YoY
Capital Expenditures
596K
-396.7% YoY
Free Cash Flow
35M
-32.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-36.4%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.